Pinsky PF, et al. - Given that raloxifene decreases breast cancer incidence, researchers sought to assess if it also reduces mortality from breast cancer. Using Surveillance Epidemiology and End Results-Medicare, they identify women with invasive breast cancer diagnosed from 2007 to 2015 at ages 65–89 who had prior Medicare Part D (prescription drug) enrollment. Breast cancer–specific survival was assessed employing two methods that utilized proportional hazards models; in method 1, survival was estimated adjusting for demographics, mammography use, and chronic conditions in the subset with Medicare fee-for-service enrollment; and in method 2, predicted survival as a function of breast cancer characteristics was modeled in nonusers and the model applied to users (≥ 180 days in past year) to predict survival. They assessed a total of 116,317 raloxifene nonusers and 1,223 regular users. Hormone receptor-negative cancers were more frequent, but T2+, N1+, and metastatic disease were less frequent among users. Nonusers and regular users exhibited 10,869 and 101 breast cancer–related deaths, respectively. They identified no worse breast cancer–specific survival in raloxifene users vs nonusers, producing indirect evidence that raloxifene decreases breast cancer–related mortality.